###begin article-title 0
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Target Cell APOBEC3C Can Induce Limited G-to-A Mutation in HIV-1
###end article-title 0
###begin p 1
###xml 912 913 912 913 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 290 295 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 353 358 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 692 699 <span type="species:ncbi:9606">patient</span>
###xml 708 713 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1282 1287 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The evolutionary success of primate lentiviruses reflects their high capacity to mutate and adapt to new host species, immune responses within individual hosts, and, in recent years, antiviral drugs. APOBEC3G (A3G) and APOBEC3F (A3F) are host cell DNA-editing enzymes that induce extensive HIV-1 mutation that severely attenuates viral replication. The HIV-1 virion infectivity factor (Vif), expressed in vivo, counteracts the antiviral activity of A3G and A3F by inducing their degradation. Other APOBECs may contribute more to viral diversity by inducing less extensive mutations allowing viral replication to persist. Here we show that in APOBEC3C (A3C)-expressing cells infected with the patient-derived HIV-1 molecular clones 210WW, 210WM, 210MW, and 210MM, and the lab-adapted molecular clone LAI, viral G-to-A mutations were detected in the presence of Vif expression. Mutations occurred primarily in the GA context and were relatively infrequent, thereby allowing for spreading infection. The mutations were absent in cells lacking A3C but were induced after transient expression of A3C in the infected target cell. Inhibiting endogenous A3C by RNA interference in Magi cells prevented the viral mutations. Thus, A3C is necessary and sufficient for G-to-A mutations in some HIV-1 strains. A3C-induced mutations occur at levels that allow replication to persist and may therefore contribute to viral diversity. Developing drugs that inhibit A3C may be a novel strategy for delaying viral escape from immune or antiretroviral inhibition.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 148 151 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 190 193 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 291 294 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 426 431 <span type="species:ncbi:9606">human</span>
###xml 503 508 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 549 556 <span type="species:ncbi:9606">patient</span>
###xml 853 858 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV has shown a chameleon-like nature, always changing to adapt to its environment. Defining the factors that drive and regulate genetic changes in HIV over time is key to understanding how HIV causes disease and escapes from the body's immune responses and drug treatment. The diversity of HIV has implications for the development of effective drugs and for fostering better immune responses. In this study, we showed that a human protein, called APOBEC3C (A3C), could induce certain mutations in some HIV-1 strains, including those derived from a patient who had developed rapid drug resistance. Eliminating the expression of this protein prevented the mutations in two different types of cells. Furthermore, short-term A3C expression was sufficient to cause mutation. We conclude that A3C is necessary and sufficient to induce signature mutations in HIV-1. A3C-induced mutations may provide potential benefit for the virus if the mutation rate is low enough such that the majority of viruses are able to replicate, while accumulating a limited number of novel mutations that may allow the virus to survive in the face of antiviral drugs or immune responses.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b001">1</xref>
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b002">2</xref>
###xml 424 425 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b003">3</xref>
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b004">4</xref>
###xml 532 540 <span type="species:ncbi:9606">patients</span>
###xml 606 609 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The evolutionary success of primate lentiviruses is evident from their prevalence in Old-World primates and their capacity to spread to new host species, frequently leading to the emergence of zoonotic disease [1,2]. Establishing persistent infection in individual hosts requires high mutation rates and rapid and extensive viral adaptation, which allows the virus to escape from humoral and cell-mediated immune responses [3,4]. Rapid viral adaptation also produces drug resistance that limits the effectiveness of therapy in many patients. Thus, understanding lentiviral genetic variation is crucial for HIV therapy.
###end p 6
###begin p 7
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b005">5</xref>
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b006">6</xref>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b010">10</xref>
###xml 292 293 292 293 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 298 299 298 299 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</underline>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b011">11</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b015">15</xref>
###xml 367 368 367 368 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 373 374 373 374 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</underline>
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b011">11</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b012">12</xref>
###xml 438 439 438 439 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 445 446 445 446 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 485 486 485 486 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 493 494 493 494 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 497 498 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b012">12</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b016">16</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b017">17</xref>
###xml 26 29 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 562 567 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 577 585 <span type="species:ncbi:9606">patients</span>
An important mechanism of HIV genetic variation is G-to-A mutation during reverse transcription [5,6]. Such mutations can be mediated by a family of DNA-editing enzymes with a strong preference for specific dinucleotide contexts [7-10]. For instance, APOBEC3G (A3G) induces high frequency of GG-to-AG mutations [11-15] whereas APOBEC3B (A3B) and APOBEC3F (A3F) cause GA-to-AA mutations [7,11,12]. In contrast, APOBEC3C (A3C) acts on both GA and GG dinucleotides, with a preference for GA over GG [7,12,16]. G-to-A mutations have been detected in at least 43% of HIV-1-infected patients, indicating that such mutations occur in a setting of persistent replication [17].
###end p 7
###begin p 8
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b015">15</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b018">18</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b022">22</xref>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b016">16</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b023">23</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b024">24</xref>
###xml 528 529 528 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b009">9</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b023">23</xref>
###xml 49 54 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 332 335 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 442 447 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 521 526 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A3G- and A3F-induced mutations are suppressed by HIV-1 virion infectivity factor (Vif), which is typically expressed in vivo, thus limiting their contribution to the adaptation of viral populations [15,18-22]. In contrast, A3B and A3C are relatively resistant to the effects of Vif [7,16,23], which suggests they may play a role in HIV diversity. However, unlike A3C [24], A3B is not expressed in the lymphoid cells that serve as targets for HIV-1 infection, which limits its potential role in the evolution of wild-type HIV-1 [9,23].
###end p 8
###begin p 9
###xml 40 43 40 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b024">24</xref>
###xml 564 565 564 565 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 571 572 571 572 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 584 585 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b012">12</xref>
###xml 710 711 710 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 712 713 712 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b009">9</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b024">24</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b025">25</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b016">16</xref>
###xml 193 198 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 476 481 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 703 708 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 879 884 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 950 955 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We hypothesized that G-to-A mutation in vif-expressing viruses is caused by an APOBEC that does not have a strong antiviral activity, is relatively resistant to Vif action, and is expressed in HIV-1 target cells. To contribute to the adaptation of viral populations, the APOBEC activity should be weak/moderate, such that mutations are sufficiently infrequent to allow some mutant progeny to survive. APOBEC3C (A3C) is a candidate because it is expressed in cells targeted by HIV-1, including PBMC, macrophages, and thymocytes [24]. A3C can cause mutations in the GA and GG contexts [7,12]. A3C has diverged by at least 40% from the A3G, A3F, and A3B, which are known to have antiviral activity against HIV-1 [7,9,24,25]. Furthermore, a recent report showed that APOBEC3C exerts potent antiviral activity against simian immuno-deficiency virus, but not to a lab-adapted clone of HIV-1 [16]. Low-level activity of DNA-editing enzymes would allow some HIV-1 progeny to be viable enough to be selected by immune responses or antiviral drugs.
###end p 9
###begin p 10
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif-</italic>
###xml 301 304 301 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag</italic>
###xml 309 312 309 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro</italic>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b026">26</xref>
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 327 332 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 342 349 <span type="species:ncbi:9606">patient</span>
In this study, we assessed the influence of A3C on G-to-A mutation and HIV-1 replication using multiple infectious viruses differing in Gag and/or Pro. The first group of isogenic vif-expressing NL4-3 molecular clones (210WW, 210WM, 210MM, 210MW) contain combinations of pre- (W) and post-therapy (M) gag and pro genes from an HIV-1-infected patient who rapidly developed resistance to a protease inhibitor-containing regimen [26]. A second group of drug-resistant viruses includes three NL4-3-based molecular clones with point mutations introduced in the protease and reverse transcriptase (RT) genes. NL4-3 and LAI were also included as controls.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
A3C Expression Is Required for G-to-A Mutation in Magi and 293T Cells
###end title 12
###begin p 13
###xml 210 218 210 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g001">Figure 1</xref>
###xml 553 561 553 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g002">Figure 2</xref>
###xml 855 858 855 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">env</italic>
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 110 115 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To determine whether A3C is responsible for inducing G-to-A mutation in HIV-1, we inhibited A3C expression in HIV-1-infected Magi cells and examined the viral sequences. Magi cells, which normally express A3C (Figure 1), were transfected with siRNA 1 targeting A3C RNA at position 167-185 relative to the start codon. A FITC-conjugated RNA oligo was cotransfected to mark the transfected cells. FITC-positive cells were sorted 48 h after transfection. We found that no A3C mRNA was detectable in FITC-positive cells transfected with A3C-specific siRNA (Figure 2A, lane 3) after 48 h in culture. By contrast, cells transfected with a control, scrambled RNA, had normal A3C mRNA levels. The cells were then infected in a single-round replication assay with NL4-3 and 210WW viruses produced by 293T transfection (both virus stocks were p24-normalized, delta env and VSV-G-pseudotyped). After an additional 24 h in culture, cellular DNA and RNA were extracted. A3C mRNA was undetectable by RT-PCR (unpublished data).
###end p 13
###begin title 14
Expression of APOBEC mRNAs in Different Cells
###end title 14
###begin p 15
Poly A+ RNA was isolated from individual cell types and APOBEC reading frames (A3B, A3C, A3F, and A3G) were amplified with primers specific for a single ORF. The specificity of the primers was verified by sequencing the PCR products. RT-PCR reactions for A3B, A3C, A3G, and A3F ORFs were analyzed by agarose gel electrophoresis. PCR templates were cDNAs for the indicated cell types or plasmids specific for A3B, A3C, A3G, or A3F (positive controls). Water was the nontemplate control (NTC), beta-actin was the internal control, and reactions lacking reverse transcriptase (RT) were also used as control during cDNA preparation (unpublished data).
###end p 15
###begin title 16
Inhibition of A3C Expression and G-to-A Mutation by siRNA 1
###end title 16
###begin p 17
(A) Magi cells were transfected with siRNA 1 (50 nM) against A3C or with scrambled RNA. A FITC-conjugated oligo was cotransfected and FITC-positive cells were sorted 48 h following transfection. PolyA+ RNA was isolated, and RT-PCR was performed with primers specific for A3B (lanes 1 and 2), A3C (lanes 3 and 4), A3F (lanes 5 and 6), and A3G (lanes 7 and 8). beta-Actin (lanes 9 and 10) was used as an internal control. A sample lacking template DNA (lane 11) was used as a negative control. Lane 12 is a molecular weight standard.
###end p 17
###begin p 18
(B) The transfected cells were infected with the VSV-G-pseudotyped 210WW and collected 24 h later. Viral DNA was amplified using the sensitive mutation assay and population sequencing was performed to analyze G-to-A mutation. The G-to-A mutation typically appeared as a mixture of G and A peaks at a given position, with G, the wild-type sequence, as the predominant peak. A change from G-to-A was considered a true mutation only if A represented at least 20% of the peak.
###end p 18
###begin p 19
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b017">17</xref>
###xml 357 358 357 358 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 367 368 367 368 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 384 405 384 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
The presence of G-to-A mutations in NL4-3 and 210WW was then examined using a sensitive mutation assay adapted from Janini et al., 2000 [17] and designed for detecting G-to-A viral mutants over a more abundant wild-type background. This assay sensitively detects G-to-A mutants in the viral population and measures the relative frequency of mutation in the GA versus GG contexts (see Materials and Methods for a detailed description).
###end p 19
###begin p 20
###xml 91 99 91 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g002">Figure 2</xref>
###xml 226 234 226 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g002">Figure 2</xref>
###xml 392 393 392 393 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 399 400 399 400 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 430 431 430 431 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 464 465 464 465 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 471 472 471 472 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 484 485 484 485 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 488 496 488 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g002">Figure 2</xref>
We found no G-to-A mutation in virus grown in Magi cells transfected with the A3C siRNA 1 (Figure 2B). By contrast, G-to-A mutations were detected in a parallel experiment where Magi cells were transfected with scrambled RNA (Figure 2B), indicating that A3C can induce G-to-A mutations in 210WW. The dinucleotide context of G-to-A mutation also correlates with the activity of A3C since both GA and GG contexts were modified with GA relatively more preferred than GG (17 GA over five GG, Figure 2B). Surprisingly, no G-to-A mutations were detected in NL4-3 infections of Magi cells transfected with the siRNA 1 or with the scrambled RNA (unpublished data).
###end p 20
###begin p 21
###xml 217 225 217 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g002">Figure 2</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b027">27</xref>
###xml 337 345 337 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g002">Figure 2</xref>
To confirm that the siRNA 1 was specific to A3C, we examined the expression profile of other APOBEC genes. We found that the Magi cell line did not express mRNA for A3G or A3F, either before or after siRNA treatment (Figure 2A, lanes 5-8). Magi cells do express A3B [27], but A3B mRNA levels were not altered by the A3C siRNA treatment (Figure 2A, lanes 1 and 2) as expected because there were nine nucleotide mismatches between the A3C siRNA 1 and A3B mRNA sequences.
###end p 21
###begin p 22
###xml 277 286 277 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0030153-sg003">Figure S3</xref>
To ensure that the suppression of G-to-A mutations in siRNA 1-transfected cells is not due to an off-target effect of the siRNA, we repeated these experiments with a second siRNA (siRNA 2), which targets residues 107-125, and causes a partial knockdown of A3C mRNA expression (Figure S3). When transfected into 293T cells, endogenous A3C mRNA levels were reduced by 74% and the frequency of G-to-A mutations was correspondingly reduced by 70% compared to the control scrambled RNA. siRNA 2 was specific for A3C mRNA; no reduction in A3B, A3F, and A3G expression was observed compared to the scrambled control.
###end p 22
###begin p 23
###xml 112 120 112 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g002">Figure 2</xref>
Thus, specific inhibition of A3C expression by siRNA eliminated 210WW G-to-A mutations after infection of Magi (Figure 2B) and 293T cells. This result suggests that A3C expression is required for the induction of G-to-A mutations in 210WW.
###end p 23
###begin title 24
A3C Expression in SupT1 Cells Is Sufficient for G-to-A Mutation
###end title 24
###begin p 25
###xml 168 176 168 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g001">Figure 1</xref>
###xml 358 379 358 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 562 570 562 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g003">Figure 3</xref>
###xml 722 730 722 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g003">Figure 3</xref>
###xml 796 799 796 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">env</italic>
###xml 1011 1013 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b017">17</xref>
###xml 1109 1110 1109 1110 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 1203 1211 1203 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g003">Figure 3</xref>
###xml 1330 1338 1330 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g003">Figure 3</xref>
###xml 627 632 <span type="species:ncbi:9606">human</span>
###xml 1398 1405 <span type="species:ncbi:9606">patient</span>
###xml 1444 1449 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To further confirm that A3C in the target cells was responsible for the G-to-A mutations, the A3C gene was transfected into SupT1 cells, which do not express A3C mRNA (Figure 1). A3C cDNA was cloned into an expression plasmid that expresses the bicistronic A3C-IRES-GFP under the R PGK promoter and carries the influenza hemaggluttinin (HA) epitope tag (see Materials and Methods). A3C expression in 293T-transfected cells was confirmed by western blotting with a polyclonal antibody specific for HA, displaying the predicted electrophoretic mobility of 23 kDa (Figure 3A). The A3C expression plasmid was then transfected into human SupT1 cells and the level of protein expression was assessed by quantifying GFP by FACS (Figure 3B). After 48 h, the cells were infected with p24 normalized delta env VSV-G pseudotyped NL4-3 and 210WW viruses produced by 293T cells. After an additional 24 h, DNA was extracted, amplified using the sensitive mutation assay for detecting G-to-A mutation in the viral population [17], and sequenced. In SupT1 cells transfected with A3C, G-to-A mutation was predominately in the GA context with 210WW showing significantly higher levels of mutation in comparison to NL4-3 (Figure 3C). No mutation was detected following infection with 210WW or NL4-3 in SupT1 cells transfected with the empty vector (Figure 3C). Therefore, A3C is sufficient to induce mutations in the patient-derived infectious molecular clone of HIV-1.
###end p 25
###begin title 26
Effect of A3C Expression in SupT1
###end title 26
###begin p 27
(A) The A3C gene cloned into the pTT-IRES-GFP lentiviral vector with an HA tag was expressed in 293T cells, and the protein detected with a polyclonal HA antibody.
###end p 27
###begin p 28
(B) This construct was used to transfect SupT1 cells. After 48 h, transfection efficiency of the construct was monitored by FACS analysis of GFP expression.
###end p 28
###begin p 29
###xml 354 355 354 355 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 361 362 361 362 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(C) Transfected SupT1 cells were infected with the VSV-G-pseudotyped 210WW and NL4-3 HIV-1 and collected 24 h later. Viral DNA was amplified using the sensitive mutation assay, and population sequencing performed to analyze G-to-A mutation. The total number of G-to-A mutations in the protease region (positions 2255-2485) was counted separately for the GA and GG contexts. No mutations were detected after infection of SupT1 cells transfected with an empty vector. ND, non-detectable mutations.
###end p 29
###begin title 30
The Replication Kinetics of 210WW Are Not Reduced Compared to NL4-3 after Spreading Infection in Cells Expressing A3C
###end title 30
###begin p 31
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b009">9</xref>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b016">16</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b027">27</xref>
###xml 553 561 553 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g001">Figure 1</xref>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 641 649 641 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g001">Figure 1</xref>
###xml 845 853 845 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g004">Figure 4</xref>
###xml 707 712 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Because 210WW and NL4-3 have different mutation frequencies in the presence of A3C in a setting of single-round infection, we wanted to assess the influence of A3C-induced mutation on the viral replication kinetics in a spreading infection. 293T-derived viruses were normalized by p24 and used to inoculate PBMC, CEMSS, and SupT1 cells, three cell types that have different APOBEC expression profiles. Consistent with previous reports, we found that PBMC expressed A3C, A3G, and A3F [9,16], and that SupT1 was negative for all APOBEC RNA analyzed [27] (Figure 1). In contrast to a previous study [7], we found that CEMSS expressed A3C only (Figure 1). Viral replication kinetics were monitored by measuring HIV-1 p24 concentration in the culture supernatant. We found that 210WW and NL4-3 had comparable growth kinetics in all three cell types (Figure 4A).
###end p 31
###begin title 32
G-to-A Mutation of Wild-Type Virus in PBMC and Different Cell Lines
###end title 32
###begin p 33
###xml 210 215 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Growth kinetics of 210WW and NL4-3 in PBMC, CEMSS, and SupT1 cells. Cells were infected with p24-normalized viral particles produced from transfected 293T cells. Virus production was monitored by measuring HIV-1 p24 concentration in the culture supernatant. The data presented are one from four independent experiments, in which comparable results were obtained.
###end p 33
###begin p 34
###xml 387 388 387 388 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 394 395 394 395 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(B) G-to-A mutation in HIV-1 strains 210WW and NL4-3. DNA was isolated from cell cultures 5 d after infection; the viral protease gene was amplified using the sensitive mutation assay for detecting G-to-A mutated templates. PCR products were then sequenced as a population. The total number of G-to-A mutations in the protease region (positions 2255-2485) was counted separately for the GA and GG contexts. ND, non-detected mutations.
###end p 34
###begin p 35
###xml 20 21 20 21 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 27 28 27 28 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
(C) Analysis of the GA and GG contexts of the protease gene in the different group of viruses after 7 d of H9 and CEMSS infections. The results presented are the mean and the standard deviations (error bars) of at least three independent infection experiments.
###end p 35
###begin p 36
###xml 296 304 296 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g004">Figure 4</xref>
###xml 365 366 365 366 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 372 373 372 373 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 389 390 389 390 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 405 406 405 406 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b012">12</xref>
###xml 477 485 477 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g004">Figure 4</xref>
###xml 579 587 579 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g004">Figure 4</xref>
###xml 668 676 668 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g004">Figure 4</xref>
The presence and sequence context of G-to-A mutations in NL4-3 and 210WW was next examined in the three cell types at day 5 post infection using the same sensitive mutation assay as above. Frequent G-to-A mutations were found in 210WW sequences extracted from PBMC and CEMSS cells (A3C-positive, Figure 4B). Consistent with A3C activity, they were detected both at GA and GG contexts with GA preferred to GG [7,12]. In contrast, no G-to-A mutation was detected in SupT1 cells (Figure 4B); although the viruses had achieved comparable levels of replication as in the other cells (Figure 4A). NL4-3 sequences showed little to no mutation in any of the three cell types (Figure 4B). Therefore, A3C does not seem to reduce the replication kinetics during spreading infection of 210WW in comparison to NL4-3 despite their difference in A3C susceptibility.
###end p 36
###begin title 37
The Frequency of Lethal Mutations Induced by A3C Is Low in Cells Expressing A3C
###end title 37
###begin p 38
###xml 244 265 241 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 795 816 789 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
To understand why A3C-induced mutations did not reduce the replication kinetics of 210WW we assessed the number of stop codons present in a region of RT using a quantitative assay based on blue and white beta-galactosidase complementation (see Materials and Methods). In this assay, the wild-type RT sequence gives rise to a blue colony whereas a mutated sequence containing a stop codon will give rise to a white colony. At day 5 post infection by 210WW, cellular DNA from PBMC, CEMSS, and SupT1 were amplified using primers that cannot distinguish between mutated and non-mutated sequences. The PCR fragments, containing six tryptophan codons susceptible to become stop codons if G-to-A mutations occur, were inserted in frame with the beta-galactosidase gene. After validating the assay (see Materials and Methods), we counted the number of white and blue colonies obtained from the different infections. In SupT1 cells infected with 210WW, four out of 1,219 clones were white (0.3%). This rate is equivalent to the background of the assay. Upon sequencing, the few white clones that were found contained insertion-deletion mutations leading to frame-shifts, rather than G-to-A mutations leading to stop codons, consistent with the absence of A3C in SupT1 cells. In contrast, 78 out of 937 clones from PBMC were white (8.3%), and 61 out of 1,290 clones from CEMSS were white (4.7%). The low frequencies of lethal mutations (4%- 8%) induced in A3C-expressing cells could explain the comparable kinetics observed between 210WW, which is susceptible to A3C, and NL4-3, which is relatively resistant.
###end p 38
###begin title 39
The Overall Rate of G-to-A Mutations in the Viral Population Is Low in Cells Expressing A3C
###end title 39
###begin p 40
###xml 247 250 247 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro</italic>
###xml 516 524 516 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vif</italic>
###xml 795 803 791 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vif</italic>
###xml 1137 1145 1126 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g004">Figure 4</xref>
###xml 1220 1228 1209 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vif</italic>
###xml 1266 1269 1251 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro</italic>
The low frequency of lethal mutation suggests that the overall rate of G-to-A mutation within the viral population should also be low in cells expressing A3C. In order to quantify the overall mutation rate, a clonal analysis of a 230-nt region of pro in proviral DNA of 210WW and NL4-3 infection from PBMC was performed. Neutral primers that do not distinguish between mutated and non-mutated sequences were used to amplify 210WW and NL4-3 DNA from PBMC that had been infected 5 d earlier. PBMC infection with NL4-3 Deltavif virus served as a positive control for G-to-A mutation. Of 45 210WW clones, 33 were wild type and 12 were mutated (27%), with only one to two G-to-A mutations each in the region analyzed. Of 47 NL4-3 clones, 43 were wild type and four were mutated (8%). Of 41 clones of Deltavif virus, four were wild type and 37 were mutated (90%). We then determined the frequency of mutations leading to lethal premature stop codons: four of 45 (9%) contained premature stop codons consistent with the result of the blue and white beta-galactosidase complementation assay and the non-attenuated replication kinetics of 210WW (Figure 4A). Two of 47 (4%) NL4-3 clones had lethal stop codons, and 28 of 41 (68%) Deltavif clones had lethal stop codons in the pro gene.
###end p 40
###begin title 41
G-to-A Mutation May Generate Drug-Resistance Mutations
###end title 41
###begin p 42
###xml 194 197 194 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro</italic>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b028">28</xref>
###xml 321 322 321 322 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 455 463 455 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vif</italic>
###xml 69 76 <span type="species:ncbi:9606">patient</span>
To investigate whether G-to-A mutation could enhance the capacity of patient-derived viruses to adapt to antiviral drugs, we screened mutated clones for drug-resistance mutations. We looked for pro D30N, a mutation in the protease gene that occurs during nelfinavir treatment [28] and is caused by G-to-A mutation in the GA context. Such a modification was found in two of 45 (4%) 210WW clones in the absence of drug selection but in none of the NL4-3 or Deltavif clones. These results suggest that limited G-to-A mutation could be deleterious for some viral progeny, but surviving progeny may have greater genetic diversity that could allow adaptation to antiviral drugs.
###end p 42
###begin title 43
A3C-Induced G-to-A Mutations Are Not Restricted to 210WW Isolates
###end title 43
###begin p 44
###xml 385 388 385 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag</italic>
###xml 393 396 393 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro</italic>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b026">26</xref>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b026">26</xref>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b029">29</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b030">30</xref>
###xml 936 938 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b026">26</xref>
###xml 1112 1121 1112 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0030153-sg002">Figure S2</xref>
###xml 1343 1351 1343 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g004">Figure 4</xref>
###xml 1484 1492 1484 1492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g001">Figure 1</xref>
###xml 1741 1742 1741 1742 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 1762 1763 1762 1763 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 1817 1825 1817 1825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g004">Figure 4</xref>
###xml 2030 2031 2030 2031 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 2190 2198 2190 2198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g004">Figure 4</xref>
###xml 311 316 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 410 417 <span type="species:ncbi:9606">patient</span>
To determine if A3C-induced G-to-A mutation occurs in viruses other than 210WW, and to correlate the susceptibility for G-to-A mutation to Gag and/or Pro, we examined G-to-A mutation in a number of viruses. The first group is the 210 virus family (210WW, 210MW, 210WM, and 210MM) that consists of reconstructed HIV-1 molecular clones derived from combinations of pre- and post-therapy gag and pro genes from a patient who had developed resistance to ritonavir within 4 wk of treatment and that were cloned into a NL4-3 genetic background [26]. These molecular clones demonstrate substantially different phenotypes with respect to drug susceptibility, replication capacity, and Gag cleavage characteristics [26,29,30]. The difference in replication capacity between 210WW and 210WM is 5-fold. The chimeric viruses (MW and WM) have intermediate phenotypes representing a 2.5-fold difference in replication capacity with respect to 210WW [26]. There are 11 amino acid differences between the wild-type Gag in 210WW and the mutant Gag in 210MM as well as two amino differences between wild type and mutant protease (Figure S2). The second group consists of RT- and protease inhibitor-resistant viruses constructed by site-directed mutagenesis of NL4-3 (Protease Mutant 1, 2, and JF4A). NL4-3 and LAI were also used. We repeated the experiments in Figure 4B using an expanded number of viruses from 293T transfections and substituting H9 cells for PBMC (also A3C-, A3G-, and A3F-positive, Figure 1). Population sequencing followed by the dinucleotide context analysis of G-to-A mutations was performed on cellular DNA at day 7 post infection using the G-to-A sensitive detection assay. Preferential (approximately 15-fold) G-to-A mutation in the GA as opposed to the GG context was seen in 210WW, 210WM, 210MW, and 210MM (Figure 4C). Susceptibility to G-to-A mutation was not restricted to the 210 viruses: LAI showed an intermediate to low level of mutation in H9 and CEMSS. G-to-A mutations in LAI also occurred predominantly in the GA context. The 210 viruses showed significantly higher levels of mutation in comparison to the other NL4-3-based and LAI viruses tested in H9 and CEMSS cells (Figure 4C). No mutations were detected in SupT1 cell infections with any of the viruses tested.
###end p 44
###begin title 45
Target Cell Effect of A3C
###end title 45
###begin p 46
###xml 428 436 428 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g004">Figure 4</xref>
###xml 575 582 575 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0030153-t001">Table 1</xref>
To determine whether A3C from the producer cell, target cell, or both induces G-to-A mutations, we measured mutations in A3C-positive and A3C-negative target cells from viruses derived from A3C-positive 293T cells directly, or after propagation for 7 d in A3C-negative cells (SupT1). Viral infection titers were normalized by supernatant Gag p24. Infections were carried out and G-to-A mutations were determined as described in Figure 4B. We found no G-to-A mutations in non-expressing A3C target cells infected with 210WW regardless of A3C expression in the producer cells (Table 1). However, G-to-A mutations were induced in target cells expressing A3C. The result suggests that only A3C in the target cell is active.
###end p 46
###begin p 47
Detection of G-to-A Mutations in 210WW Virus Produced in either A3C-Positive or AC3-Negative Cells following Infection of AC3-Positive and AC3-Negative Cells
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 584 585 584 585 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 591 592 591 592 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 685 686 685 686 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 725 726 725 726 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 737 738 737 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b005">5</xref>
###xml 739 740 739 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b006">6</xref>
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b017">17</xref>
###xml 782 783 782 783 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 823 824 823 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 825 827 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b012">12</xref>
###xml 828 830 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b016">16</xref>
###xml 974 975 974 975 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 986 994 986 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g004">Figure 4</xref>
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 151 158 <span type="species:ncbi:9606">patient</span>
###xml 178 183 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1106 1111 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In this study, we asked whether A3C has a role in HIV-1 G-to-A mutations. We found that transient A3C expression was sufficient to cause mutation of a patient-derived infectious HIV-1 molecular clone in SupT1 cells. Reciprocally, specific abrogation of A3C expression prevented G-to-A mutation in Magi and 293T cells, demonstrating that A3C is required for mutation in these cell lines. Furthermore, G-to-A mutation is detected in CEMSS cells, which we found express A3C but not A3B, A3F, or A3G. A role for A3C in PBMC is suggested by the activity of the enzyme that can act on both GA and GG contexts: Both mutational patterns are widely observed in vivo with G-to-A mutation in the GA context more predominant than in the GG context [5,6,17]. The preferential activity of A3C on GA context reported by previous studies [7,12,16] is consistent with our findings. Indeed, in CEMSS cells that endogenously express only A3C, G-to-A mutation was predominately detected in the GA context (Figure 4B). These data are consistent with the notion that A3C is necessary and sufficient to induce G-to-A mutation in HIV-1.
###end p 49
###begin p 50
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b017">17</xref>
###xml 342 343 342 343 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 352 353 352 353 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
G-to-A mutations occurring at low rates in a high background of wild-type viruses were detected in this study using a sensitive G-to-A detection assay adapted from Janini et al, 2000 [17]. Although this approach is useful to sensitively detect G-to-A mutations in the viral population, and to assess the relative frequency of mutation in the GA versus GG context, it is not quantitative. To confirm and quantify the rate of mutation detected in A3C-expressing cells we used the blue and white complementation assay and clonal analysis of sequences.
###end p 50
###begin p 51
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b016">16</xref>
###xml 1105 1107 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b028">28</xref>
###xml 1472 1481 1472 1477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vif,</italic>
###xml 601 606 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The blue and white complementation assay and clonal analysis of gene segments amplified using non-selective primers indicated that the majority of viral sequences was not altered after exposure to A3C: 27% of the 210WW clones harbor only one to two G-to-A mutations. We also found that mutated sequences containing premature stop codons induced by G-to-A mutation reflect less than 9% of the 210WW clones. A low rate of G-to-A mutation likely explains the negligible antiviral effect of A3C on the 210 and LAI viruses. Other studies reported that A3C did not exhibit strong antiviral activity against HIV-1 NL4-3 replication, which is consistent with our own observations [7,16]. The minimal antiviral effect of A3C reflects the low frequencies of mutation documented in blue and white complementation assay and clonal analysis of virus populations. Limited G-to-A mutation associated with A3C may be deleterious for some viral progeny, but surviving progeny would have greater genetic diversity. Protease D30N mutations, which confer clinically important resistance to the protease inhibitor nelfinavir [28], appeared in 5% of 210WW clones from PBMC infections. While other proteins expressed in PBMCs may have contributed to the D30N mutations observed, A3C is a likely inducer for the following reasons: A3C is expressed in PBMCs; D30N mutations were observed exclusively in infections with 210WW, which is susceptible to A3C, but not in infections with NL4-3 or NL4-3 Deltavif, which are susceptible to other deaminases; and all three viruses have the same reverse transcriptase, suggesting that reverse transcriptase errors could not account for the differential rates of mutation observed in the different infections.
###end p 51
###begin p 52
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b026">26</xref>
###xml 742 752 742 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0030153-sg001">Figures S1</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0030153-sg002">S2</xref>
###xml 782 785 782 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag</italic>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 97 104 <span type="species:ncbi:9606">patient</span>
###xml 766 773 <span type="species:ncbi:9606">patient</span>
The action of A3C was observed primarily in infectious molecular clones of HIV-1, derived from a patient who rapidly developed drug resistance and virological drug failure during therapy with a protease inhibitor [26]. G-to-A mutation associated with A3C expression was also observed in the molecular clone LAI, which may suggest that A3C action is not restricted to the 210 viruses. Susceptibility to A3C-mediated mutation was higher in the 210 family of viruses compared to the NL4-3 family of viruses. The mechanism for this difference in susceptibility to A3C is not known, although the 210 family of viruses differs from NL4-3 in Gag and Pro (the DNA alignment as well as the amino acid alignment of 210WW, LAI, and NL4-3 is provided in Figures S1 and S2). The patient-derived gag segment in 210 is 6% divergent from NL4-3 overall. Differences in Gag may alter the stability of the viral core, or the pre-integration complex, which would affect how long nascent single-stranded cDNA is available to bind with A3C in the target cell. More work is needed to identify the viral determinants of A3C susceptibility, and to seek clinical correlations of A3C susceptibility.
###end p 52
###begin p 53
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b031">31</xref>
###xml 699 707 699 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030153-g001">Figure 1</xref>
###xml 805 812 805 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0030153-t001">Table 1</xref>
The action of A3C differs from that of A3G, A3F, and A3B in several ways. A3G appears to act both in the virion and the target cell: target cell action appears to involve impaired reverse transcription rather than cytidine deamination [31]. A3G, A3F, and A3B cause G-to-A hypermutation when incorporated in the budding virion, producing lethal hypermutation early in the synthesis of viral cDNA that frequently occurs in the virion. In contrast, A3C seems to act only in the target cell based on the following observations: G-to-A mutation was not observed in SupT1 cells (using the sensitive and the blue and white assays) that were infected with viruses produced in 293T cells, which express A3C (Figure 1), while viruses propagated in SupT1 acquire mutation only when they infect A3C-expressing cells (Table 1). Target cell action was further demonstrated by transient expression or transient knockdown of A3C in target cells, which determined the appearance of G-to-A mutation in single-cycle infections. The exposure of the viral cDNA to A3C in the target cell could be limited, which may decrease the frequency of viral mutation to sublethal levels, allowing surviving progeny to have greater genetic diversity to adapt and escape from immune responses or antiviral drugs.
###end p 53
###begin p 54
###xml 149 152 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b032">32</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b033">33</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b034">34</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b033">33</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b034">34</xref>
###xml 623 626 623 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b032">32</xref>
###xml 861 864 861 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 940 941 940 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 942 943 942 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b009">9</xref>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b016">16</xref>
###xml 998 999 998 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b007">7</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b019">19</xref>
###xml 1003 1005 1003 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b035">35</xref>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b036">36</xref>
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 63 66 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 296 301 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1251 1256 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV diversity is the major obstacle for effective treatment of HIV patients. It has been suggested that natural genetic variations in A3G/A3F and/or vif may result in an incomplete neutralization of those cytidine deaminases allowing the remaining enzymes to exert a low level of mutation on the HIV-1 genome and potentially inducing viral diversity [32,33,34]. Although A3G mutants have been recovered from different individuals, there is no functional evidence for a defect in the antiviral activity of those mutants and in their ability to induce massive hypermutation resulting in defective viruses [33,34]. Similarly, vif variants that partially fail to neutralize A3G have been identified; however, the recovered proviral sequences were highly hypermutated and replication-defective [32]. We find evidence of a low level of cytosine deaminase activity in vif-expressing viruses, although some Vif-A3C interactions have been observed [7,9,16]. A3C activity may be relatively resistant to Vif [7,19,35,36] because A3C has a tyrosine instead of the aspartic acid at position 128, which is critical for the interaction with and sensitivity to Vif. In conclusion, we demonstrate here that A3C is necessary and sufficient for G-to-A mutations in some HIV-1 strains. A3C-induced mutations occur at levels that allow replication to persist and may therefore play a role in driving viral diversity.
###end p 54
###begin title 55
Materials and Methods
###end title 55
###begin title 56
Cells and viruses.
###end title 56
###begin p 57
###xml 538 539 537 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 594 595 593 594 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sc>
###xml 344 349 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 671 676 <span type="species:ncbi:9606">human</span>
The cell lines H9, CEMSS, SupT1, Magi, and 293T were directly obtained from the National Institutes of Health AIDS Research and Reference Reagent Program. Cell line identity was confirmed using DNA fingerprinting by PCR amplification with allele-specific primers (Research Genetics). PBMCs from leukocyte-enriched fractions of whole blood from HIV-1-seronegative donors were isolated by density-gradient centrifugation (Histopaque-1077, Sigma). Cells were stimulated with PHA-P (5 mug/ml, Sigma) for 24 h, washed, and maintained at 2 x 106/ml in RPMI-1640 (Irvine Scientific) supplemented with L-glutamine (2 mM), 20% FBS (Gemini Bioproducts), and IL-2 (10 U/ml purified human, Roche Diagnostics) before and after infection.
###end p 57
###begin p 58
###xml 123 128 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
pNL4-3, obtained from the NIH AIDS Research and Reference Reagent Program (Catalog Number: 114), is a laboratory wild-type HIV-1 molecular clone. pM46I/L63P/V82T/I84V (Catalog Number: 4595), and pL10R/M46I/L63P/V82T/I84V (Catalog Number: 4596) are NL4-3-based infectious molecular clones with protease mutations introduced in vitro. pJF4A (Catalog Number: 1412) is a full-length infectious molecular clone that is identical to pNL4-3 except for two nucleotide substitutions introduced by site-directed mutagenesis at nt 2754 (A-G) and 2755 (C-A) that render it resistant to ddC. pLAI.2 (Catalog Number: 2532) is a laboratory wild-type molecular clone.
###end p 58
###begin p 59
###xml 134 137 134 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag</italic>
###xml 142 145 142 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro</italic>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b026">26</xref>
###xml 346 355 346 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag, gag,</italic>
###xml 360 363 360 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro</italic>
###xml 400 409 400 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0030153-sg001">Figure S1</xref>
###xml 167 174 <span type="species:ncbi:9606">patient</span>
###xml 346 349 <span type="species:ncbi:103820">gag</span>
###xml 351 354 <span type="species:ncbi:103820">gag</span>
The 210 viruses are isogenic infectious molecular clones having the NL4-3 background and combinations of pre-therapy and post-therapy gag and pro gene segments from a patient who had developed resistance mutations to ritonavir 4 wk after treatment [26]. The 210 constructs differ from NL4-3 in a portion of the 5' untranslated region upstream of gag, gag, and pro (nt 702-2563 relative to NL4-3; see Figure S1).
###end p 59
###begin p 60
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag</italic>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro,</italic>
###xml 64 67 64 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag</italic>
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro,</italic>
###xml 92 95 92 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro</italic>
###xml 147 150 147 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag</italic>
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro,</italic>
###xml 201 204 201 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag</italic>
###xml 222 226 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro.</italic>
210WW has pre-therapy gag and pro, while 210MM has drug-adapted gag and pro, which contains pro mutations I54V and V82A. 210WM has the pre-therapy gag with drug-adapted pro, and 210MW has drug-adapted gag with pre-therapy pro.
###end p 60
###begin p 61
###xml 6 14 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;env</italic>
###xml 25 33 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;env</italic>
###xml 431 433 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b037">37</xref>
###xml 471 476 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
NL4-3 Deltaenv and 210WW Deltaenv viruses were generated by digesting each plasmid with Nhe1 restriction enzyme (Invitrogen). The DNA polymerase I Klenow fragment (New England Biolabs) was used to fill in the ends and the plasmids were religated using the T4 DNA ligase (Promega). Pseudotyped VSV-G DeltaEnv NL4-3 and 210WW viruses were produced by cotransfecting 293T with the pMD.G plasmid expressing the VSV-G envelope protein [37] and the plasmid expressing DeltaEnv HIV-1 viruses, respectively.
###end p 61
###begin p 62
###xml 5 13 5 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vif</italic>
###xml 72 75 68 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
NL43 Deltavif is a NL4-3 variant with three stop codons introduced into vif by directed mutagenesis (C. de Noronha, unpublished data).
###end p 62
###begin title 63
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 replication and infectivity.
###end title 63
###begin p 64
###xml 522 523 516 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 542 550 536 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;env</italic>
###xml 148 153 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Virus stocks were prepared by Lipofectamine-mediated transfection of 293T cells. The clarified viral supernatants were quantified and normalized by HIV-1 Gag p24 ELISA (Perkin Elmer). DNase treatment of viral supernatant was carried out at 37 degreesC for 30 min with the equivalent of 10 units DNase (Sigma)/1 ml of the clarified crude virus. Spreading infections were monitored over time by accumulation of p24 Gag in the culture supernatants. Single-cycle infectivity was performed by challenging the cell lines (5 x 105 cells) with VSV-G Deltaenv pseudotyped viruses for 24 h.
###end p 64
###begin title 65
APOBEC plasmid construction.
###end title 65
###begin p 66
PolyA+ RNA was isolated from cells with the QuickPrep Micro mRNA Purification Kit (Pharmacia). The open reading frames of A3B, A3C, A3F, and A3G were amplified by RT-PCR with the following primers: 3B forward 5'-ATGAATCCACAGATCAGAAATCC-3' and reverse 5'-TCAGTTTCCCTGATTCTGG-3'; 3C: forward 5'-ATGAATCCACAGATCAGAAACC-3' and reverse 5'-TCACTGGAGACTCTCCCGTA-3'; 3F: forward 5'-ATGAAGCCTCACTTCAGAAAC-3' and reverse 5'-TCACTCGAGAATCTCCTGC-3'; 3G: forward 5'-ATGAAGCCTCACTTCAGAAACACAG-3' and reverse 5'-TCAGTTTTCCTGATTCTGGAGAATGG-3'. The amplicons were cloned into pGEM-T easy vectors (Promega) and confirmed by sequencing. The A3C gene with HA tag sequence at its 3' terminus was amplified from mRNA of H9 cells by RT-PCR, and the identity of the product was confirmed by sequencing. It was then cloned into pTT-IRES-GFP (a gift from David Fenard, Gladstone Institute of Virology and Immunology) for protein expression.
###end p 66
###begin title 67
Transfection.
###end title 67
###begin p 68
The 293T or Magi cells were transfected with Lipofectamine 2000 transfection reagent (Invitrogen), according to the manufacturer's recommendations. The SupT1 cells were transfected by Amaxa electroporation technology with the program T29, according to the manufacturer's recommendations.
###end p 68
###begin title 69
Nucleic acid isolation, RT, PCR, and DNA sequencing.
###end title 69
###begin p 70
DNA was extracted from infected cells with the DNA Easy kit (Invitrogen) and quantified by spectrometry. PolyA + RNA was isolated with QuickPrep Micro mRNA Purification kit (Pharmacia). Reverse transcription reaction was performed with random hexamers using SuperScript III reverse transcriptase (Invitrogen). An RT minus control was always performed in parallel to check for DNA contamination. PCR was performed with Easy-A High Fidelity PCR Cloning Enzyme (Stratagene). APOBEC reading frames (A3B, A3C, A3F, and A3G) were amplified with primers specific for a single gene and listed above in the APOBEC plasmid construction section. The specificity of the primers was verified by sequencing the PCR products. The PCR products were sequenced by dye terminator cycle sequencing with Big Dye v3.1 (Applied Biosystems) or ET Terminators (Amersham Biosciences) on an ABI 3100 microcapillary sequencer. Raw sequence data was analyzed and aligned using Sequencher (Gene Codes).
###end p 70
###begin title 71
Sensitive mutation assay for the detection of G-to-A mutation.
###end title 71
###begin p 72
###xml 226 227 226 227 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 233 234 233 234 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 260 263 260 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro</italic>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b017">17</xref>
###xml 254 259 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
This assay is designed to detect G-to-A viral mutated sequences present in a high wild-type background. A nested PCR procedure specific for a 230-nt region in the protease gene amplifies both G (wt) and A (mut) species in the GA and GG context using the HIV-1 pro primers Hypa 10 and Hypa 11 in the first PCR and DP 16 and DP 17 in the second round PCR as described [17].
###end p 72
###begin p 73
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030153-b017">17</xref>
The first round PCR uses primers specific for the mutated sequences (Hypa 10 and Hypa 11). The goal is to enrich the mutated sequences that are usually present in low concentration. The second round PCR uses primers that can amplify both mutated (if present from the first round PCR) and the input wild-type DNA (carried over from the first PCR) [17]. Under these amplification conditions, no PCR-induced mutations were detected using control plasmids as templates. Protease sequences were determined as population sequences. A mixture of G and A peaks was typically seen at the mutation site. A change from G-to-A was considered a true mutation only if A represented at least 20% of the mixture.
###end p 73
###begin title 74
Clonal analysis.
###end title 74
###begin p 75
The clonal analysis was performed using the neutral primers DP16-2 and DP17-2. The sequence of DP16-2 is 5'-TATCCTTTAGCTTCCCTCA-3'. The sequence of DP17-2 is 5'-TAATGGGAAAATTTAAAGTGCAG-3'. PCR products were cloned in pCR 4-TOPO (Invitrogen). The plasmids were then sequenced and analyzed for their G-to-A content.
###end p 75
###begin title 76
Blue and white beta galactosidase complementation assay.
###end title 76
###begin p 77
###xml 85 88 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pol</italic>
###xml 263 294 263 294 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTCCTAAAT TTAAATTACC CATACAAAA</bold>
###xml 326 348 326 348 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAAGGGAGGG GTATTGA-3&#8242;.</bold>
###xml 567 571 567 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lacZ</italic>
###xml 824 840 824 840 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Escherichia coli</named-content>
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 824 840 <span type="species:ncbi:562">Escherichia coli</span>
The genetic assay was carried out with a 111-nucleotide viral DNA containing a HIV-1 pol fragment that includes six tryptophan codons susceptible to become stop codons if G-to-A mutations occur. Viral DNA was amplified using the primers Nsi-Trp6 Fw: 5'-CCA ATGCATACTCCTAAAT TTAAATTACC CATACAAAA-3' and Trp6 Rev Spe: 5'-GACTAGTTAAGGGAGGG GTATTGA-3'. The amplified DNA was phenol extracted, precipitated with ethanol, subjected to treatment with Nsi1 and SpeI, and then purified from a 1% agarose gel. This fragment encoding six Trp codons was cloned in frame into the lacZ fragment of the pGEM-T vector. For this purpose pGEM-T was digested first with Nsi1 and then with SpeI to obtain the linearized vector, which was purified from a 1% agarose gel and treated with alkaline phosphatase before ligation to the PCR products. Escherichia coli XL-1 Blue was transformed and plated onto minimal agar plates containing 8% X-Gal (5-bromo-4-chloro-3-indolyl-d-galactopyranoside) and 20% IPTG (isopropyl-d-thiogalactopyranoside). The plates were incubated at 37 degreesC for approximately 15 h. We validated the assay by first mixing 0%-5%-25%-50%-75%-100% of G-to-A mutated clones with wild-type clones. We then amplified each mix, cloned the PCR product, and counted the number of blue and white colonies. We confirmed that the number of blue and whites clones obtained after every specific mixture with the level of mutated sequences included in the mix. We also determined that the background of this assay was around 0.3%, which corresponded to the percentage of white colonies detected using 100% wild-type plasmids. The sequences of the white clones obtained in this specific mix revealed insertions or deletions interrupting the reading frame, and not stop codons. We also sequenced 20 white and 20 blue clones obtained from the other mix to verify their mutation content and the presence of stop codons. 20/20 blue clones were wild-type sequences and 20/20 white clones were mutated sequences. Blue and white clones were counted using the EagleSight (Stratagene) instrument and confirmed by manual counting.
###end p 77
###begin title 78
Western blot analysis.
###end title 78
###begin p 79
A3C protein expression in 293T transfected cells was detected by western blot with an HA-probe (Y-11) and HRP polyclonal antibody specific for the HA tag (Santa Cruz Biotechnology).
###end p 79
###begin title 80
RNAi assay.
###end title 80
###begin p 81
siRNAs targeting A3C from positions 167-185 (siRNA 1) and 107-125 (siRNA 2) bases relative to the start codon were transcribed in vitro (RiboMax kit, Promega) from an oligo DNA template containing the T7 promoter synthesized by Invitrogen. The sequence of the scrambled RNA for both siRNAs was generated with the Promega siRNA target designer.
###end p 81
###begin p 82
###xml 99 100 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
For the siRNA transfection, 293T and Magi cells were seeded into six-well plates at a density of 104 cells/ml. After about 2 h, purified A3C siRNAs along with RNA oligo conjugated to FITC (Block It kit, Invitrogen) were transfected into the cells with Lipofectamine 2000, according to the manufacturer's protocols. A scrambled siRNA was transfected separately as a control.
###end p 82
###begin p 83
The efficiency of transfection was monitored by fluorescent microscopy at 24, 48, and 72 h after siRNA transfection. For flow cytometry analysis, the cells were analyzed with a Becton Dickinson FACS cytometer. Samples were counted and analyzed with FlowJo software (Tree Star). Non-transfected cells were used as a control. FITC-positive cells were sorted (DIVA instrument, Becton Dickinson) for further analysis and infection.
###end p 83
###begin title 84
Supporting Information
###end title 84
###begin title 85
Nucleic Acid Alignment of 210WW, 210MM, NL4-3, and LAI Viruses
###end title 85
###begin p 86
###xml 77 86 77 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag, gag,</italic>
###xml 91 94 91 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pro</italic>
###xml 77 80 <span type="species:ncbi:103820">gag</span>
###xml 82 85 <span type="species:ncbi:103820">gag</span>
The alignment includes the segment of the 5' untranslated region upstream of gag, gag, and pro (nt 702-2563 relative to NL4-3). The dots indicate the nucleotides that match.
###end p 86
###begin p 87
(704 KB AI).
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin title 89
Amino Acid Alignment of 210WW, 210MM, NL4-3, and LAI Viruses
###end title 89
###begin p 90
(A) Gag amino acid alignment of 210WW, 210MM, NL4-3, and LAI viruses. Amino acid position relative to polyprotein start in HXB2: 1-513. Residue numbers for each line of sequence are provided. The dots indicate the residues that match.
###end p 90
###begin p 91
(B) Protease alignment of 210WW, 210MM, NL4-3, and LAI viruses. Amino acid position relative to polyprotein start in HXB2: 557-655.
###end p 91
###begin p 92
(500 KB AI).
###end p 92
###begin p 93
Click here for additional data file.
###end p 93
###begin title 94
Partial Reduction of A3C Expression and G-to-A Mutation by siRNA 2
###end title 94
###begin p 95
(A) 293T cells were transfected with siRNA 2 (50 nM) against A3C or with scrambled RNA. A FITC-conjugated oligo was cotransfected and FITC-positive cells were sorted 48 h following transfection. PolyA+ RNA was isolated, and RT-PCR was performed with primers specific for A3B (lanes 1 and 2), A3C (lanes 3 and 4), A3F (lanes 5 and 6), and A3G (lanes 7 and 8). beta-Actin (lanes 9 and 10) was used as an internal control. A sample lacking template DNA (lane 11) was used as a negative control. Lane 12 is a molecular weight standard.
###end p 95
###begin p 96
(B) The transfected cells were infected with the VSV-G-pseudotyped 210WW and collected 24 h later. Viral DNA was amplified using the sensitive mutation assay and population sequencing was performed to analyze G-to-A mutation. The G-to-A mutation typically appeared as a mixture of G and A peaks at a given position, with G, the wild-type sequence, as the predominant peak. A change from G-to-A was considered a true mutation only if A represented at least 20% of the peak.
###end p 96
###begin p 97
(C) Base composition of 210WW plasmid, 210WW DNA infection of 293T + scrambled RNA, and 210WW DNA infection of 293T + siRNA 2 in the region amplified by the sensitive mutation assay.
###end p 97
###begin p 98
(786 KB AI).
###end p 98
###begin p 99
Click here for additional data file.
###end p 99
###begin title 100
Accession Numbers
###end title 100
###begin p 101
###xml 162 169 162 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag-pro</italic>
###xml 186 193 186 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag-pro</italic>
###xml 212 219 212 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag-pro</italic>
###xml 242 249 242 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag-pro</italic>
The GenBank () accession numbers for the genes and proteins mentioned in the text are: A3B (NM_004900), A3C (NM_014508), A3F (NM_001006666), A3G (NM_021822), LAI gag-pro (K02013), NL4-3 gag-pro (AF324493), 210MM gag-pro (EU100418), and 210WW gag-pro (EU100417).
###end p 101
###begin p 102
###xml 164 172 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vif</italic>
We thank Robert Hance, Jerry Kropp, and Jeanny Lee for outstanding technical assistance; Carlos de Noronha, David Feinard, and Warner Greene for provision of NL4-3 Deltavif and the pTT vector; and Francois Clavel for the 210 plasmids. We also thank Christophe Kreis for careful review of the manuscript and Maria Warmerdam for helpful discussions. We thank Francoise Chanut for her excellent work on manuscript editing.
###end p 102
###begin title 103
Abbreviations
###end title 103
###begin p 104
APOBEC3B
###end p 104
###begin p 105
APOBEC3C
###end p 105
###begin p 106
APOBEC3F
###end p 106
###begin p 107
APOBEC3G
###end p 107
###begin p 108
hemaggluttinin
###end p 108
###begin p 109
reverse transcriptase
###end p 109
###begin p 110
virion infectivity factor
###end p 110
###begin title 111
References
###end title 111
###begin article-title 112
###xml 45 80 <span type="species:ncbi:11712">simian immunodeficiency virus SIVsm</span>
###xml 125 128 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 142 177 <span type="species:ncbi:11709">human immunodeficiency virus type 2</span>
###xml 239 253 <span type="species:ncbi:9531">sooty mangabey</span>
Genetic characterization of new West African simian immunodeficiency virus SIVsm: Geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop
###end article-title 112
###begin article-title 113
AIDS as a zoonosis: Scientific and public health implications
###end article-title 113
###begin article-title 114
###xml 0 28 <span type="species:ncbi:12721">Human immunodeficiency virus</span>
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition
###end article-title 114
###begin article-title 115
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
###end article-title 115
###begin article-title 116
###xml 43 71 <span type="species:ncbi:12721">human immunodeficiency virus</span>
A new type of G->A hypermutation affecting human immunodeficiency virus
###end article-title 116
###begin article-title 117
###xml 52 87 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Selection, recombination, and G--A hypermutation of human immunodeficiency virus type 1 genomes
###end article-title 117
###begin article-title 118
Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities
###end article-title 118
###begin article-title 119
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA
###end article-title 119
###begin article-title 120
Cytidine deamination of retroviral DNA by diverse APOBEC proteins
###end article-title 120
###begin article-title 121
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Hypermutation of HIV-1 DNA in the absence of the Vif protein
###end article-title 121
###begin article-title 122
Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: Correlation with mutation spectra in vivo
###end article-title 122
###begin article-title 123
RNA-editing enzyme APOBEC1 and some of its homologs can act as DNA mutators
###end article-title 123
###begin article-title 124
###xml 32 37 <span type="species:ncbi:9606">human</span>
Broad antiretroviral defense by human APOBEC3G through lethal editing of nascent reverse transcripts
###end article-title 124
###begin article-title 125
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
###end article-title 125
###begin article-title 126
DNA deamination mediates innate immunity to retroviral infection
###end article-title 126
###begin article-title 127
###xml 47 76 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication
###end article-title 127
###begin article-title 128
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
###xml 109 116 <span type="species:ncbi:9606">patient</span>
Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells
###end article-title 128
###begin article-title 129
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability
###end article-title 129
###begin article-title 130
###xml 104 107 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor
###end article-title 130
###begin article-title 131
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 79 84 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins
###end article-title 131
###begin article-title 132
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif
###end article-title 132
###begin article-title 133
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif
###end article-title 133
###begin article-title 134
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif
###end article-title 134
###begin article-title 135
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22
###end article-title 135
###begin article-title 136
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 50 85 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication
###end article-title 136
###begin article-title 137
###xml 47 82 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
###end article-title 137
###begin article-title 138
###xml 30 33 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G
###end article-title 138
###begin article-title 139
###xml 45 80 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
###end article-title 139
###begin article-title 140
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 62 67 <span type="species:ncbi:9606">human</span>
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
###end article-title 140
###begin article-title 141
###xml 24 27 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 101 106 <span type="species:ncbi:9606">human</span>
Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues
###end article-title 141
###begin article-title 142
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells
###end article-title 142
###begin article-title 143
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Natural variation in Vif: Differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification
###end article-title 143
###begin article-title 144
###xml 29 64 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation
###end article-title 144
###begin article-title 145
APOBEC3G genetic variants and their influence on the progression to AIDS
###end article-title 145
###begin article-title 146
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion
###end article-title 146
###begin article-title 147
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation
###end article-title 147
###begin article-title 148
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
###end article-title 148
###begin p 149
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. All authors conceived and designed the experiments and analyzed the data. KB performed the experiments and contributed reagents/materials/analysis tools. KB and RMG wrote the paper.
###end p 149
###begin p 150
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. The research was supported by the NIH (HD 40543-04), the Gladstone-UCSF Center for AIDS Research (P30 AI27763-12), and funds from the J. David Gladstone Institutes.
###end p 150
###begin p 151
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 151

